Next Article in Journal
Aspirin Prevention of Colorectal Cancer: Focus on NF-κB Signalling and the Nucleolus
Previous Article in Journal
Development of Phosphorothioate DNA and DNA Thioaptamers
Previous Article in Special Issue
CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
Biomedicines 2017, 5(3), 42;

Targeting of Tumor Neovasculature with GrB/VEGF121, a Novel Cytotoxic Fusion Protein

Department of Experimental Therapeutics, UT M.D. Anderson Cancer Center, Houston, TX 77030, USA
Author to whom correspondence should be addressed.
Received: 24 May 2017 / Revised: 7 July 2017 / Accepted: 11 July 2017 / Published: 17 July 2017
(This article belongs to the Special Issue Targeted Human Cytolytic Fusion Proteins)
Full-Text   |   PDF [4868 KB, uploaded 17 July 2017]   |  


Angiogenesis is a critical process in numerous diseases, and intervention in neovascularization has therapeutic value in several disease settings, including ocular diseases, arthritis, and in tumor progression and metastatic spread. Various vascular targeting agents have been developed, including those that inhibit growth factor receptor tyrosine kinases, blocking antibodies that interfere with receptor signal transduction, and strategies that trap growth factor ligands. Limited anti-tumor efficacy studies have suggested that the targeted delivery of the human pro-apoptotic molecule Granzyme B to tumor cells has significant potential for cancer treatment. Here, we review biological vascular targeting agents, and describe a unique vascular targeting agent composed of Granzyme B and the VEGF receptor ligand VEGF121. The fusion protein GrB/VEGF121 demonstrates cytotoxicity at nanomolar or sub-nanomolar levels, excellent pharmacokinetic and efficacy profiles, and has significant therapeutic potential targeting tumor vasculature. View Full-Text
Keywords: Granzyme B; fusion protein; angiogenesis; vascular targeting Granzyme B; fusion protein; angiogenesis; vascular targeting

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Mohamedali, K.A.; Rosenblum, M.G. Targeting of Tumor Neovasculature with GrB/VEGF121, a Novel Cytotoxic Fusion Protein. Biomedicines 2017, 5, 42.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top